New trial in primary progressive multiple sclerosis for Laquinimod - TopicsExpress



          

New trial in primary progressive multiple sclerosis for Laquinimod Teva Pharmaceutical Industries Ltd. and Active Biotech today announced the expansion of the laquinimod clinical development program with the initiation of the ARPEGGIO trial, which will evaluate the potential of laquinimod to treat primary progressive multiple sclerosis (PPMS) There are no approved therapies available for the treatment of PPMS beyond symptom management...... Read More - ms-uk.org/laquinimod
Posted on: Tue, 04 Nov 2014 14:52:32 +0000

Trending Topics




© 2015